Ribotek Biopharmaceuticals

Ribotek is a South Korean biotechnology company specializing in the discovery of novel therapeutic targets and the development of RNA-based medicines through its proprietary ribosome profiling (Ribo-seq) platform. Founded by Professor Yoon Ki Kim of Seoul National University, the company focuses on the translatome—the comprehensive set of mRNA molecules undergoing translation—to identify disease-specific protein synthesis patterns that are invisible to standard transcriptomics. This approach allows Ribotek to pinpoint precise regulatory mechanisms in protein production, facilitating the design of small molecules and RNA therapeutics for oncology, fibrosis, and neurodegenerative diseases. The company's technology is particularly effective in addressing conditions characterized by dysregulated protein synthesis or ribosome-associated quality control failures. Ribotek is currently in the pre-clinical stage, leveraging its platform to build a robust pipeline of precision medicines.